European Urology published a clinical update in Research Highlights on 25 Feb 2026. The item focuses on Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Review the original article for the full source wording and details.
De Santis M, Palou Redorta J, Nishiyama H, et al